Article

Beyond Traditional IP: Addressing Regulatory Barriers

2023-01-05

Abstract excerpt

The COVID pandemic has underscored that IP can limit the ability to addressing public health crises because IP owners have the legal right to bar others from making needed supplies. However, what is less well understood yet critical to making medical treatments available are IP-related barriers existing in regulatory laws that complement traditional IP protection. In other words, even if a potential manufacture...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a9f8d171-66b9-51aa-9a4d-a93aaa2cde0c
DOI: 10.2139/ssrn.4314183

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Beyond Traditional IP: Addressing Regulatory BarriersDOI 10.2139/ssrn.4314183Read

Addressing Exclusivity Issues During the COVID-19 Pandemic and BeyondSemantic proximity Read

Avoiding the TRIPS Trap: A Path to Domestic Disclosure of Clinical Drug Data Consistent with International NormsSemantic proximity Read

The Role of Intellectual Property Rights on Access to Medicines in the WHO African Region: 25 Years After the TRIPS AgreementSemantic proximity Read

The Intellectual Property of COVID-19Semantic proximity Read

COVID-19 Trade Secrets and Information Access: An OverviewSemantic proximity Read

Compelling Trade Secret TransfersSemantic proximity Read

Prepared Oral Statement of Professors David S. Levine and Joshua D. Sarnoff in ITC Investigation 332-996, on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and Trips Agreement FlexibilitiesSemantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Recalibrating Patent Protection for COVID-19 Vaccines: A Path to Affordable Access and Equitable DistributionSemantic proximity Read

Deficiency Patterns in FDA Complete Response Letters for New Drug and Biologics Applications: A Cross-Sectional AnalysisSemantic proximity Read

Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read